Physician profile
Daniel A Litovsky
NPI 1275583403
$1,365.09
in general payments reported to CMS, 2019-2025
29 companies · $70.44 in 2025
The $70.44 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $77.00 · 2022: $301 · 2023: $326 · 2024: $258 · 2025: $70.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617 · Debt Forgiveness: $37.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.82 |
| Debt Forgiveness | $37.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $132.83 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $102.59 | 2019-2024 | |
| Novo Nordisk INC | $100.39 | 2019-2025 | Wegovy |
| Medtronic, INC. | $91.66 | 2024 | Interstim |
| Abbvie INC. | $91.32 | 2023-2024 | |
| Lilly USA, LLC | $89.21 | 2022-2024 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $84.26 | 2019-2020 | |
| Amgen INC. | $75.22 | 2019-2024 | Otezla, Repatha, Prolia |
| Glaxosmithkline, LLC. | $67.87 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.10 | 2020-2023 | Xifaxan |
| Amarin Pharma, INC. | $40.43 | 2019-2022 | |
| Bausch Health US, LLC | $39.61 | 2022-2024 | Wellbutrin |
| Astellas Pharma US INC | $38.41 | 2019-2023 | Myrbetriq |
| Baxter Healthcare | $37.86 | 2023 | |
| Inspire Medical Systems, INC. | $37.24 | 2023-2024 | Inspire |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $28.75 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $24.82 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $24.74 | 2019 | |
| Abbott Laboratories | $23.86 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.82 | 2023 | Gvoke Hypopen |
| Inari Medical, INC. | $20.77 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Daiichi Sankyo INC. | $20.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.49 | 2024 | |
| Sumitomo Pharma America, INC. | $17.97 | 2025 | Gemtesa |
| Boston Scientific Corporation | $17.95 | 2019 | |
| Esperion Therapeutics, INC. | $16.28 | 2022 | |
| Shire North American Group INC | $14.42 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.14 | 2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $12.83 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Litovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.